Jacob Vogelstein is the Co-Founder and Managing Partner of Catalio Capital Management, LP. He is primarily responsible for managing the firm and for making investments in private breakthrough biomedical technology companies. He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee.
Jacob currently serves on the Boards of Boost Neuroscience, Blackrock Neurotech, Cage Pharmaceuticals, Iambic, ManaT Bio, Nextpoint and Pheast Therapeutics.
Prior to founding Catalio, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun-out of T. Rowe Price, where he focused on making biomedical technology investments. Earlier in his career, Jacob served on the faculty at Johns Hopkins University, at both the Applied Physics Laboratory and the Whiting School of Engineering.
Jacob has received widespread recognition for his innovative work in biomedical engineering including the Presidential Early Career Award in Science and Engineering, which is the highest honor bestowed by the US Government on science and engineering professionals in the early stages of their careers.
Jacob earned his BSc. degree in Bio-Electrical Engineering from Brown University and his Ph.D. degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.